$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-K Financial Statement

#000153217614000008 Filed on February 13, 2014

Income Statement

Concept	2012 Q4	2012 Q3	2012 Q2
Revenue	$414.6M	$427.7M	$304.4M
YoY Change	237.14%	315.9%	182.35%
Cost Of Revenue	$30.20M	$20.15M	$21.84M
YoY Change	906.67%	4376.67%	5360.75%
Gross Profit	$384.4M	$407.5M	$282.6M
YoY Change	220.33%	298.06%	163.09%
Gross Profit Margin	92.72%	95.29%	92.82%
Selling, General & Admin	$57.70M	$46.88M	$47.71M
YoY Change	58.95%	42.43%	93.92%
% of Gross Profit	15.01%	11.5%	16.88%
Research & Development	$181.0M	$158.3M	$147.4M
YoY Change	40.31%	23.74%	2.99%
% of Gross Profit	47.09%	38.84%	52.16%
Depreciation & Amortization	$9.700M	$9.400M	$9.400M
YoY Change	22.78%	13.25%	18.99%
% of Gross Profit	2.52%	2.31%	3.33%
Operating Expenses	$238.7M	$205.2M	$195.1M
YoY Change	44.32%	27.57%	16.33%
Operating Profit	$145.7M	$202.4M	$87.48M
YoY Change	-420.93%	-446.18%	-245.07%
Interest Expense	-$11.50M	$11.41M	$11.24M
YoY Change	21.05%	181.04%	-380.9%
% of Operating Profit	-7.89%	5.64%	12.84%
Other Income/Expense, Net	$400.0K	-$10.90M	-$10.74M
YoY Change	-50.0%	225.64%	-1173.5%
Pretax Income	$134.6M	$191.5M	$76.74M
YoY Change	-348.8%	-409.8%	-221.05%
Income Tax	-$335.8M
% Of Pretax Income	-249.48%
Net Earnings	$470.4M	$191.5M	$76.74M
YoY Change	-980.2%	-407.01%	-222.78%
Net Earnings / Revenue	113.46%	44.77%	25.21%
Basic Earnings Per Share	$4.92	$2.02	$0.81
Diluted Earnings Per Share	$4.08	$1.72	$0.70
COMMON SHARES
Basic Shares Outstanding		95.01M shares	94.59M shares
Diluted Shares Outstanding		115.8M shares	110.2M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$308.0M	$263.0M	$301.0M
YoY Change	-41.56%	7.35%	-2.9%
Cash & Equivalents	$230.3M	$119.0M	$171.9M
Short-Term Investments	$78.00M	$144.0M	$129.0M
Other Short-Term Assets	$183.0M	$55.00M	$8.000M
YoY Change	408.33%	243.75%	-57.89%
Inventory	$28.64M	$29.57M	$24.00M
Prepaid Expenses
Receivables	$593.2M	$506.7M	$435.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.206B	$948.6M	$769.0M
YoY Change	81.14%	179.0%	86.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$379.9M	$372.9M	$372.0M
YoY Change	3.26%	2.45%	2.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$271.0M	$313.0M	$288.0M
YoY Change	-1.81%	21.32%	14.74%
Other Assets	$23.10M	$18.32M	$28.00M
YoY Change	270.01%	-12.75%	40.0%
Total Long-Term Assets	$874.5M	$712.0M	$689.0M
YoY Change	32.94%	10.73%	8.68%
TOTAL ASSETS
Total Short-Term Assets	$1.206B	$948.6M	$769.0M
Total Long-Term Assets	$874.5M	$712.0M	$689.0M
Total Assets	$2.080B	$1.661B	$1.458B
YoY Change	57.19%	68.93%	39.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$39.00M	$22.00M	$26.00M
YoY Change	39.29%	4.76%	-3.7%
Accrued Expenses	$72.00M	$102.0M	$101.0M
YoY Change	5.88%	75.86%	83.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.000M
YoY Change
Total Short-Term Liabilities	$163.6M	$178.6M	$183.0M
YoY Change	10.3%	34.26%	34.56%
LONG-TERM LIABILITIES
Long-Term Debt	$456.0M	$450.0M	$445.0M
YoY Change	4.83%	183.02%	179.87%
Other Long-Term Liabilities	$7.259M	$6.987M	$235.0M
YoY Change	12.66%	-97.33%	-14.23%
Total Long-Term Liabilities	$7.259M	$6.987M	$680.0M
YoY Change	12.66%	-98.34%	57.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$163.6M	$178.6M	$183.0M
Total Long-Term Liabilities	$7.259M	$6.987M	$680.0M
Total Liabilities	$835.1M	$854.6M	$863.0M
YoY Change	-0.33%	53.98%	51.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$517.1M	-$987.5M
YoY Change	-59.2%
Common Stock		$94.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.257B	$806.0M	$594.7M
YoY Change
Total Liabilities & Shareholders Equity	$2.080B	$1.661B	$1.458B
YoY Change	57.19%	68.93%	39.26%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2012 Q2
OPERATING ACTIVITIES
Net Income	$470.4M	$191.5M	$76.74M
YoY Change	-980.2%	-407.01%	-222.78%
Depreciation, Depletion And Amortization	$9.700M	$9.400M	$9.400M
YoY Change	22.78%	13.25%	18.99%
Cash From Operating Activities	$93.20M	-$2.400M	-$78.40M
YoY Change	-285.29%	-94.87%	130.59%
INVESTING ACTIVITIES
Capital Expenditures	-$15.10M	-$10.30M	-$12.80M
YoY Change	33.63%	15.73%	-13.51%
Acquisitions
YoY Change
Other Investing Activities	$106.3M	-$38.50M	-$126.3M
YoY Change	-570.35%	-581.25%	-180.04%
Cash From Investing Activities	$91.10M	-$48.80M	-$139.2M
YoY Change	-368.73%	5322.22%	-197.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-73.00M	-1.800M	-5.000M
YoY Change	-120.2%	500.0%	-149.5%
NET CHANGE
Cash From Operating Activities	93.20M	-2.400M	-78.40M
Cash From Investing Activities	91.10M	-48.80M	-139.2M
Cash From Financing Activities	-73.00M	-1.800M	-5.000M
Net Change In Cash	111.3M	-53.00M	-222.6M
YoY Change	-59.85%	10.42%	-286.9%
FREE CASH FLOW
Cash From Operating Activities	$93.20M	-$2.400M	-$78.40M
Capital Expenditures	-$15.10M	-$10.30M	-$12.80M
Free Cash Flow	$108.3M	$7.900M	-$65.60M
YoY Change	-377.69%	-120.84%	241.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	111345000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	250896000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	38934000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	61936000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	787071000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	593207000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	180513000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	221617000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1166000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1188000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1763508000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2045857000	USD
CY2013	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	216857000	USD
CY2012	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	4308000	USD
CY2012	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	112834000	USD
CY2011	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	22440000	USD
CY2013	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	179423000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120623000	USD
CY2011Q4	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120600000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56609000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	93800000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94181000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	200101000	USD
CY2013	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	159286000	USD
CY2012	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-824884000	USD
CY2011	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	80078000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2013Q4	us-gaap	Assets Assets	2951013000	USD
CY2012Q4	us-gaap	Assets Assets	2080490000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	1796934000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	1206012000	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	354958000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	548267000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	354990000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	548322000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	0	USD
CY2012	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	651000	USD
CY2012	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	702000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	447000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	66835000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	239812000	USD
CY2012	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	51000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	447000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	239812000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	63442000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	3393000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	351565000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	547101000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	1000000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	670000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	392000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	702000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	447000	USD
CY2011	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	400000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	100000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1300000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	304276000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	17726000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	19307000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	18897000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	18498000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	18107000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	211741000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230276000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535608000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	483610000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112572000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	371038000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	305332000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-253334000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-221131000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	424340000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	750965000	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain financial instruments, and accounts receivable. A large portion of the Company's cash is held by a few major financial institutions. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales of EYLEA and ARCALYST are due from three distributors and several specialty pharmacies, who are the Company's customers. The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. In addition, the Company may insure a portion of its accounts receivables within its overall risk management practices. As of December 31, 2013 and 2012, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> reserves against trade accounts receivable. In addition, during the years ended December 31, 2013, 2012, and 2011, the Company did </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">t recognize any charges for write-offs of trade accounts receivable. </font></div></div>
CY2013Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	320315000	USD
CY2012Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	296518000	USD
CY2011	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4216000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	118048000	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	83927000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	1344717000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	920764000	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	650983000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	201475000	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	433000	USD
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4308000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	225397000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4308000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	23489000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-300319000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	54910000	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-9000	USD
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-340156000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	63601000	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	929000	USD
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7995000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	50831000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	47000000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	184199000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	208342000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-39837000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	8700000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	88033000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	99659000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	350637000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	279314000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	340156000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	276555000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	44677000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	148134000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	192022000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	231878000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	277484000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	348151000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77119000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	135000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	23511000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	34215000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1380000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	18902000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	71164000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9372000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	109715000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	53367000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2486000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1830000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	6824000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	929000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	1171000	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6300000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5700000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4100000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31082000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41204000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36940000	USD
CY2012Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	99913000	USD
CY2013Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	104707000	USD
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.92
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.33
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.45
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.02
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.92
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.45
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.81
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.75
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.08
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.70
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.72
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.811
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.405
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.390
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.054
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.049
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.028
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.021
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.093
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.049
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19987000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	69429000	USD
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	4308000	USD
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	216857000	USD
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2012	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2011	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	500000	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2800000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-222892000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	414421000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	713360000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1132000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288998000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-335848000	USD
CY2012Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-335800000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	340200000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	34000000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10979000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50016000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	136684000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	198658000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21118000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	590085000	USD
CY2012	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	340200000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-27974000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-41077000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-40329000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28932000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47956000	USD
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14094000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	52765000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6612000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23684000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	0	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	552000	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	277000	USD
CY2011	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2707000	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	990000	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	4761000	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10233000	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	14231000	shares
CY2013	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1900000	USD
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	USD
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	USD
CY2012	us-gaap	Interest Expense InterestExpense	45304000	USD
CY2013	us-gaap	Interest Expense InterestExpense	46437000	USD
CY2011	us-gaap	Interest Expense InterestExpense	21282000	USD
CY2012	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	29126000	USD
CY2011	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2013	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2011	us-gaap	Interest Paid Net InterestPaidNet	14725000	USD
CY2013	us-gaap	Interest Paid Net InterestPaidNet	23842000	USD
CY2012	us-gaap	Interest Paid Net InterestPaidNet	21946000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14352000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2570000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	28638000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	70354000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4862000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9120000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14656000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	35868000	USD
CY2011	us-gaap	Inventory Write Down InventoryWriteDown	500000	USD
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	9100000	USD
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	17000000	USD
CY2011	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3549000	USD
CY2013	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	-231000	USD
CY2012	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2012000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	998937000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	835105000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2080490000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2951013000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163550000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	298835000	USD
CY2011	us-gaap	Licenses Revenue LicensesRevenue	31457000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	28506000	USD
CY2012	us-gaap	Licenses Revenue LicensesRevenue	26471000	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	158376000	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	77819000	USD
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	271230000	USD
CY2013Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	389891000	USD
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regeneron Pharmaceuticals, Inc. and its subsidiaries (collectively, the “Company” or “Regeneron”) is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company currently has three marketed products as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States, European Union ("EU"), Japan and certain other countries outside the United States for the treatment of neovascular age-related macular degeneration ("wet AMD") and macular edema following central retinal vein occlusion ("CRVO"). The Company commenced sales of EYLEA for the treatment of wet AMD in November 2011 and for the treatment of macular edema following CRVO in September 2012, following receipt of regulatory approvals in the United States. Bayer HealthCare LLC commenced sales of EYLEA for the treatment of wet AMD in the fourth quarter of 2012 following receipt of regulatory approvals outside the United States, and for the treatment of macular edema secondary to CRVO in the fourth quarter of 2013 following receipt of regulatory approvals in the EU and Japan. Regeneron is collaborating with Bayer HealthCare on the global development and commercialization of EYLEA outside the United States. Regeneron maintains exclusive rights to EYLEA in the United States and is entitled to all profits from any such sales. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ZALTRAP</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (ziv-aflibercept) Injection for Intravenous Infusion, known in the scientific literature as VEGF Trap, which is available in the United States, European Union, and certain other countries for treatment, in combination with 5-fluorouracil, leucovorin, irinotecan ("FOLFIRI"), for patients with metastatic colorectal cancer ("mCRC") that is resistant to or has progressed following an oxaliplatin-containing regimen. Marketing approval for ZALTRAP was received from the U.S. Food and Drug Administration ("FDA") in August 2012, and from the European Commission in February 2013. Regeneron and Sanofi globally collaborate on the development and commercialization of ZALTRAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (rilonacept) Injection for Subcutaneous Use, which is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes ("CAPS"), including Familial Cold Auto-inflammatory Syndrome ("FCAS") and Muckle-Wells Syndrome ("MWS"), in adults and children 12 and older. Marketing approval for ARCALYST for the treatment of CAPS was received from the FDA in 2008.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's facilities are primarily located in New York. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting pharmaceutical research, obtaining regulatory approvals, commercializing products, and obtaining and enforcing patents.</font></div></div>
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77139000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	384249000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-97646000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	128471000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-355455000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81073000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74615000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	583648000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-141682000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	750269000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-221760000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	424362000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	191468000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	76743000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	141306000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	98874000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	11651000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	96806000	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	470407000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	87376000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-221760000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	424362000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	779395000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43292000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46668000	USD
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17733000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-205159000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	760028000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	457713000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	117590000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	10934000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9606000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	9429000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	9919000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	9853000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	67849000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	9875000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7790000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	8029000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19569000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29022000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23100000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5327000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	629000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	696000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-22000	USD
CY2012Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	6550000	USD
CY2013Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	11014000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11330000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7259000	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23690000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-34049000	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6714000	USD
CY2012	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2011	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	117500000	USD
CY2013	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2011	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25078000	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	195087000	USD
CY2012	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	163300000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	470393000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	577278000	USD
CY2011	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	240391000	USD
CY2013	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	156323000	USD
CY2011	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	57217000	USD
CY2012	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	49337000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28025000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	96141000	USD
CY2013	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. </font></div></div>
CY2011	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	391107000	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2012	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63549000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57393000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43587000	USD
CY2011	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	93800000	USD
CY2012	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2011Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	93800000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	378146000	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	426356000	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	439209000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	560453000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	748600000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	526983000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	379940000	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2012Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	3800000	USD
CY2013Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	1200000	USD
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2024000	USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2203000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1667000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	625554000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	859947000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	529506000	USD
CY2012Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	8186000	USD
CY2013Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	0	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-517054000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92692000	USD
CY2012	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	423814000	USD
CY2011	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	326609000	USD
CY2013	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	430111000	USD
CY2013	us-gaap	Revenue Recognition Interest RevenueRecognitionInterest	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment Income</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income, which is included in investment income, is recognized as earned.</font></div></div>
CY2013Q4	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	25000000	USD
CY2012Q4	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	10000000	USD
CY2012Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	65000000	USD
CY2013Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	45000000	USD
CY2013	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales consist of U.S. sales of EYLEA and ARCALYST. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated. The Company's written contracts with its customers stipulate product is shipped freight on board destination (FOB destination). The Company records revenue from product sales upon delivery to its customers. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in the United States to three distributors and several specialty pharmacies. The Company sells ARCALYST in the United States to two specialty pharmacies. Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product. For EYLEA, the distributors and specialty pharmacies generally sell the product directly to healthcare providers, whereas for ARCALYST, the specialty pharmacies sell the product directly to patients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Rebates and Chargebacks: </font><font style="font-family:inherit;font-size:10pt;">The Company estimates reductions to product sales for Medicaid and Veterans' Administration ("VA") programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services ("PHS"), and other institutions (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution-Related Fees: </font><font style="font-family:inherit;font-size:10pt;">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Pay Discounts: </font><font style="font-family:inherit;font-size:10pt;"> No prompt pay discounts are currently offered to the Company's customers on sales of EYLEA. In connection with sales of ARCALYST, the Company offers discounts to its customers for prompt payments. The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount. Therefore, the Company accrues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the prompt pay discount that is based on the gross amount of each ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">invoice, at the time of sale.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns: </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA to healthcare providers and ARCALYST to patients using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. </font></div></div>
CY2013	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">Technology Licensing</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company's </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune</font><font style="font-family:inherit;font-size:10pt;"> technology in its internal research programs. The terms of these agreements include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company's </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune </font><font style="font-family:inherit;font-size:10pt;">technology. Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods.</font></div></div>
CY2011	us-gaap	Revenues Revenues	445824000	USD
CY2013	us-gaap	Revenues Revenues	2104745000	USD
CY2012	us-gaap	Revenues Revenues	1378477000	USD
CY2012Q2	us-gaap	Revenues Revenues	304399000	USD
CY2013Q3	us-gaap	Revenues Revenues	597027000	USD
CY2013Q4	us-gaap	Revenues Revenues	610412000	USD
CY2012Q4	us-gaap	Revenues Revenues	414602000	USD
CY2012Q1	us-gaap	Revenues Revenues	231789000	USD
CY2012Q3	us-gaap	Revenues Revenues	427687000	USD
CY2013Q1	us-gaap	Revenues Revenues	439664000	USD
CY2013Q2	us-gaap	Revenues Revenues	457642000	USD
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	858093000	USD
CY2011	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	44686000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1425839000	USD
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	117261000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	210755000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	329415000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	94157000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	56094000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	198399000	USD
CY2013Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Of Change Upper Bound SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeOfChangeUpperBound	8000000	USD
CY2012Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	63937	shares
CY2013Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	38248	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	20603	shares
CY2010Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6325000	shares
CY2011	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6979000	USD
CY2013	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	5718000	USD
CY2012	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6325000	USD
CY2010Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	174800000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43615000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	67174000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54762000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	1952076000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1245385000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	527815000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	485732000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26627000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11274000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5596000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12819000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	9415000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	572000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1873000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2192000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7620000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	8305000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3805000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	23500000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8400000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4200000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates which could have a significant impact on the Company's financial statements include provisions for product rebates, chargebacks, distribution-related fees, and returns; periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements; periods over which certain clinical trial costs are recognized; the Company's estimate of cumulative EYLEA sales through May 7, 2016 to determine a blended royalty rate as a basis for recognized royalty expense related to the Company's non-exclusive license with Genentech (see Note 13b); fair value of stock options; useful lives of property, plant, and equipment; inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value; capitalization of inventory costs associated with the Company's products prior to regulatory approval; deferred tax asset valuation allowance; and the assessment of uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the Company's collaborations with Sanofi and Bayer HealthCare:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Sanofi collaboration revenue is the Company's share of profits or losses from commercialization of ZALTRAP, </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">which is provided by Sanofi, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Bayer HealthCare collaboration revenue is the Company's share of profits or losses from commercialization of EYLEA outside the United States, which is provided by Bayer HealthCare, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in research and development expenses is the Company's share of development expenses incurred by its collaboration partners, Bayer HealthCare and Sanofi, including the Company's share of Bayer HealthCare and Sanofi estimated development expenses for the most recent fiscal quarter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These estimates for the most recent period are adjusted, if necessary, in the subsequent period to reflect actual amounts. </font></div></div>
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	18826000	USD
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2218000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24601000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	62251000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	89875000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	84100000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	45643000	USD
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13373000	shares
CY2011	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20697000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90610000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115382000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111290000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90610000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97917000	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94685000	shares
CY2011Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	6200000	USD
CY2013Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	16100000	USD
CY2012Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	8600000	USD
CY2012Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	10985000	USD
CY2013Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	23654000	USD
CY2012Q4	regn	Accrued Sales Related Deductions And Royalties AccruedSalesRelatedDeductionsAndRoyalties	21870000	USD
CY2013Q4	regn	Accrued Sales Related Deductions And Royalties AccruedSalesRelatedDeductionsAndRoyalties	66855000	USD
CY2011	regn	Adjustment To Additional Paid In Capital Cost Of Convertible Note Hedge AdjustmentToAdditionalPaidInCapitalCostOfConvertibleNoteHedge	117500000	USD
CY2013	regn	Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation	15664000	USD
CY2012	regn	Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation	50466000	USD
CY2011	regn	Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation	2638000	USD
CY2013	regn	Costofmanufacturing Costofmanufacturing	37307000	USD
CY2012	regn	Costofmanufacturing Costofmanufacturing	528000	USD
CY2011	regn	Costofmanufacturing Costofmanufacturing	0	USD
CY2013Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	34185000	USD
CY2012Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	33809000	USD
CY2013Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	107677000	USD
CY2012Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	131822000	USD
CY2013Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	12815000	USD
CY2012Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	17022000	USD
CY2012Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	76520000	USD
CY2013Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	76522000	USD
CY2013Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	18942000	USD
CY2012Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	24437000	USD
CY2012Q4	regn	Facility Lease Obligation Including Reimbursements FacilityLeaseObligationIncludingReimbursements	0	USD
CY2011Q4	regn	Facility Lease Obligation Including Reimbursements FacilityLeaseObligationIncludingReimbursements	0	USD
CY2013Q4	regn	Facility Lease Obligations Current FacilityLeaseObligationsCurrent	939000	USD
CY2012Q4	regn	Facility Lease Obligations Current FacilityLeaseObligationsCurrent	1374000	USD
CY2013Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	184258000	USD
CY2012Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	159436000	USD
CY2011	regn	Income Tax Expense Benefit Resulting From Provision In American Recovery And Reinvestment Act Of2009 IncomeTaxExpenseBenefitResultingFromProvisionInAmericanRecoveryAndReinvestmentActOf2009	700000	USD
CY2013	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	433000	shares
CY2011	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	0	shares
CY2012	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	715000	shares
CY2013	regn	Initialtermoflease Initialtermoflease	P15Y
CY2011	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	15600000	USD
CY2013	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	16200000	USD
CY2012	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	16000000	USD
CY2013	regn	Leaseextensionterms Leaseextensionterms	P5Y
CY2012Q4	regn	Marketable Debt Securities Collateral MarketableDebtSecuritiesCollateral	3200000	USD
CY2013	regn	Non Cash Interest Expense NonCashInterestExpense	23061000	USD
CY2011	regn	Non Cash Interest Expense NonCashInterestExpense	5101000	USD
CY2012	regn	Non Cash Interest Expense NonCashInterestExpense	22925000	USD
CY2013Q4	regn	Number Of Renewal Options NumberOfRenewalOptions	3
CY2013	regn	Other Collaboration Revenue OtherCollaborationRevenue	220289000	USD
CY2011	regn	Other Collaboration Revenue OtherCollaborationRevenue	43072000	USD
CY2012	regn	Other Collaboration Revenue OtherCollaborationRevenue	70099000	USD
CY2013Q4	regn	Percentage Of Prompt Pay Discount Company Accrues PercentageOfPromptPayDiscountCompanyAccrues	1
CY2013	regn	Percentage Of Start Up Costs Of Total Contract Value Maximum PercentageOfStartUpCostsOfTotalContractValueMaximum	0.20
CY2013	regn	Percentage Of Start Up Costs Of Total Contract Value Minimum PercentageOfStartUpCostsOfTotalContractValueMinimum	0.10
CY2012	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	10900000	USD
CY2013	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	11500000	USD
CY2011	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	9300000	USD
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	21192000000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes

Files In Submission

Name	View Source	Status
0001532176-14-000008-index-headers.html	Edgar Link	pending
0001532176-14-000008-index.html	Edgar Link	pending
0001532176-14-000008.txt	Edgar Link	pending
0001532176-14-000008-xbrl.zip	Edgar Link	pending
exhibit10110.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-123113x10k.htm	Edgar Link	pending
regn-20131231.xml	Edgar Link	completed
regn-20131231.xsd	Edgar Link	pending
regn-20131231_cal.xml	Edgar Link	unprocessable
regn-20131231_def.xml	Edgar Link	unprocessable
regn-20131231_lab.xml	Edgar Link	unprocessable
regn-20131231_pre.xml	Edgar Link	unprocessable
regn-ex_211x12312013x10k.htm	Edgar Link	pending
regn-ex_231x12312013x10k.htm	Edgar Link	pending
regn-ex_311x12312013x10k.htm	Edgar Link	pending
regn-ex_312x12312013x10k.htm	Edgar Link	pending
regn-ex_32x12312013x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stockpricechart201310k.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2012 Q4 Form 10-K Financial Statement

#000153217614000008 Filed on February 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2012 Q4 Form 10-K Financial Statement

#000153217614000008 Filed on February 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn